SEngine Precision Medicine Raises $10M to Advance Paris Test for Personalized Cancer Drug Treatment
Seattle startup SEngine Precision Medicine raised $10 million to advance its Paris Test, which tailors cancer drug treatments by culturing patient tumor cells and testing drug responses. The test aims to provide personalized treatment options beyond traditional genomic tests and has been used by about 800 patients so far.
No comments yet.